OncoLens develops technologies that improve cancer treatment planning, simplify tumor board management, facilitate survivorship care planning, and automate accreditation and quality reporting through an intelligent workflow engine that streamlines business processes and enables more informed clinical decision-making.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/07/20 | $2,500,000 | Pre-Series A |
Atlanta Technology Angels Robbins Fund | undisclosed |
